A large Phase IV clinical trial conducted across India has found that a once-daily fixed-dose combination of metoprolol succinate extended-release and telmisartan, marketed as Metosartan, significantly lowered blood pressure over a full 24-hour cycle in patients struggling with both essential hypertension and stable ischemic heart disease. The CONTROL-IHD study, published in the journal Advances in Therapy, used ambulatory blood pressure monitoring, the clinical gold standard for tracking blood pressure throughout ordinary daily life, and reported clinically meaningful reductions that persisted through the vulnerable early morning hours when cardiovascular events most often strike. For a country where an estimated 315 million people live with hypertension and where high systolic pressure contributes to the majority of stroke deaths, the results offer a pragmatic template for how combination therapy can be deployed in high-risk patients.
The clinical logic behind the trial rests on a well-documented problem: most patients with hypertension and coexisting ischemic heart disease cannot reach target blood pressure on a single drug. Uncontrolled blood pressure raises the risk of coronary artery disease, heart failure, and stroke by two- to four-fold, and every 20-mmHg rise in systolic pressure roughly doubles the risk of dying from ischemic heart disease. International guidelines from the American College of Cardiology, the American Heart Association, and the European societies of cardiology and hypertension now recommend early combination therapy, ideally in a single pill, particularly for patients at elevated cardiovascular risk. Fixed-dose combinations reduce pill burden, a known driver of poor adherence, while pairing drugs that act through complementary mechanisms.
The combination tested in CONTROL-IHD merges a beta-1 selective beta-blocker with an angiotensin receptor blocker. Metoprolol succinate extended-release blunts the cardiac effects of catecholamines, lowering heart rate, cardiac output, and myocardial oxygen demand, which is why beta-blockers remain central to managing ischemic heart disease. Telmisartan, a long-acting ARB, promotes vasodilation by blocking the renin-angiotensin system and is valued for its prolonged pharmacological action. The formulation employs a proprietary wrap matrix technology, a sustained-release system in which the drug is dispersed within a hydrophilic polymer matrix, designed to deliver uniform drug release over 24 hours, smooth out peak-trough fluctuations, and maintain steady plasma concentrations through the day and night.
The study enrolled 88 adults aged 18 to 65 at seven clinical sites across India. All participants had essential hypertension that remained uncontrolled despite at least four weeks of stable antihypertensive monotherapy, along with stable ischemic heart disease and a resting heart rate above 70 beats per minute. Notably, the investigators chose not to impose a washout period, judging it clinically inappropriate to withdraw background therapy from patients with uncontrolled hypertension and stable ischemic disease. Participants instead received the fixed-dose combination once daily with food for eight weeks, at either 25 mg or 50 mg of metoprolol succinate extended-release paired with 40 mg of telmisartan, with dose up-titration permitted between weeks two and four based on heart rate. In practice, no patient met the predefined criteria for dose adjustment.
The primary endpoint was the change in mean 24-hour systolic blood pressure measured by ambulatory monitoring, and the results were unambiguous. Systolic pressure fell from 143.38 mmHg at baseline to 129.03 mmHg at week eight, a mean reduction of 14.41 mmHg, while diastolic pressure dropped from 88.84 mmHg to 79.34 mmHg, a fall of 9.52 mmHg, both with p-values below 0.0001. Seventy-two patients completed the study, and similar results emerged in both the modified intent-to-treat and per-protocol populations, reinforcing the robustness of the primary analysis. By week eight, the mean 24-hour blood pressure of the group had approached the widely recommended treatment goal of below 130/80 mmHg for patients at elevated cardiovascular risk.
Several secondary findings carry particular technical interest. Ambulatory monitoring identified a responder rate of 36.62 percent, defined as achieving mean 24-hour values below 130/80 mmHg, compared with just 10.67 percent based on office measurements, a disparity that underscores how clinic readings can mask therapeutic response. Blood pressure during the last six hours of the dosing interval, a proxy for early morning control, fell by 15.21 mmHg systolic and 9.85 mmHg diastolic, indicating that the antihypertensive effect was sustained through the period immediately before the next dose, when morning surges typically elevate cardiovascular risk. Mean heart rate declined by roughly 4 to 5 beats per minute, a moderate but clinically relevant reduction in myocardial oxygen demand for patients with ischemic disease, even though few individuals reached the strict target range of 50 to 60 beats per minute.
The study also examined blood pressure variability, an emerging independent predictor of cardiovascular morbidity and mortality, using indices including the smoothness index and the treatment-on variability index. From the weeks two to four visit to week eight, the smoothness index rose by 0.15 for systolic and 0.11 for diastolic pressure, while the treatment-on variability index increased by 0.20 and 0.16 respectively, all statistically significant, reflecting progressively more consistent 24-hour blood pressure lowering. Other variability measures produced mixed signals: weighted standard deviation, average real variability, and delta diastolic pressure showed non-significant downward trends, delta systolic pressure fell significantly, and the coefficient of variation for diastolic pressure increased significantly, a finding the authors flag as warranting further investigation. Overall, the pattern suggests a trend toward a more stable blood pressure profile in selected parameters.
Safety outcomes were favorable. Twenty-one treatment-emergent adverse events were reported by 21 patients, all mild in intensity, with pruritus the most frequent at 5.7 percent. Application-site reactions were attributed to the ambulatory monitoring cuff rather than the oral medication. No serious adverse events, deaths, or discontinuations due to adverse events occurred, and physical examinations, vital signs, and electrocardiograms revealed no significant abnormalities. This tolerability profile is consistent with prior Phase III data on the same combination in Indian patients and supports the drug’s suitability for long-term use.
The authors are candid about the limitations of their design. As an open-label, single-arm study without a comparator, the observed reductions may partly reflect regression toward the mean or a Hawthorne effect from closer monitoring. The predominance of male participants, the enrollment of patients already on monotherapy, and the eight-week follow-up window all constrain generalizability, and endpoints such as target organ damage and hard cardiovascular events were not assessed. Still, the trial is the first in India to evaluate this specific fixed-dose combination using ambulatory monitoring and one of the most comprehensive endpoint analyses in this population. The investigators call for larger, randomized, event-driven trials to confirm whether the sustained blood pressure control demonstrated here translates into reduced strokes, infarctions, and deaths. For now, the study strengthens the case that a single daily pill combining a beta-blocker and an ARB can deliver smooth, round-the-clock blood pressure control for one of cardiology’s most demanding patient groups.
Subject of Research: 24-hour blood pressure control with a metoprolol succinate extended-release and telmisartan fixed-dose combination in patients with essential hypertension and stable ischemic heart disease
Article Title: CONTROL-IHD Study: 24-h BP Control with Metoprolol-Telmisartan FDC in Hypertension and Stable Ischemic Disease
Article References: Sharma, K., Chhaya, G., Chopda, M., Kaul, U., Agarwal, M., Dorairaj, P., Sethuraman, S., Bharathi, P., Dharmadhikari, S., Ahire, P., Khandhedia, C., Markandeywar, N., Mane, A., Mehta, S., & Joglekar, S. (2026). CONTROL-IHD Study: 24-h BP Control with Metoprolol-Telmisartan FDC in Hypertension and Stable Ischemic Disease. Advances in Therapy. https://doi.org/10.1007/s12325-026-03779-x
Image Credits: AI Generated
DOI: 10.1007/s12325-026-03779-x
Keywords: hypertension, ischemic heart disease, fixed-dose combination, metoprolol succinate, telmisartan, ambulatory blood pressure monitoring, blood pressure variability, cardiovascular risk, Phase IV study, combination therapy, CONTROL-IHD, Control
Cite Scienmag News
APA
MLA
Chicago
Frances Kline. (September 20, 2026). Single-Pill Combo Lowers Blood Pressure Around the Clock in Heart Disease Patients. Scienmag. https://scienmag.com/single-pill-combo-lowers-blood-pressure-around-the-clock-in-heart-disease-patients/
Frances Kline. “Single-Pill Combo Lowers Blood Pressure Around the Clock in Heart Disease Patients.” Scienmag, 20 September 2026, https://scienmag.com/single-pill-combo-lowers-blood-pressure-around-the-clock-in-heart-disease-patients/. Accessed 20 September 2026.
Frances Kline. “Single-Pill Combo Lowers Blood Pressure Around the Clock in Heart Disease Patients.” Scienmag. September 20, 2026. https://scienmag.com/single-pill-combo-lowers-blood-pressure-around-the-clock-in-heart-disease-patients/
Copy citation
Download RIS
Tags: 24-hour blood pressure loweringambulatory blood pressure monitoringblood pressure control in heart diseaseblood pressure variabilitycardiovascular riskcardiovascular risk reductioncombination therapyControlCONTROL-IHDessential hypertension and ischemic heart diseasefixed-dose combinationfixed-dose combination therapyhypertensionhypertension management in IndiaHypertension Treatmentischemic heart diseasemetoprolol succinatemetoprolol succinate extended-releasePhase IV clinical trialPhase IV studysingle-pill antihypertensivetelmisartan
